AR088764A1 - Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas - Google Patents

Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Info

Publication number
AR088764A1
AR088764A1 ARP120103710A ARP120103710A AR088764A1 AR 088764 A1 AR088764 A1 AR 088764A1 AR P120103710 A ARP120103710 A AR P120103710A AR P120103710 A ARP120103710 A AR P120103710A AR 088764 A1 AR088764 A1 AR 088764A1
Authority
AR
Argentina
Prior art keywords
sensory
methods
motor
aminopiridins
impediment
Prior art date
Application number
ARP120103710A
Other languages
English (en)
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Publication of AR088764A1 publication Critical patent/AR088764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se divulgan aquí métodos y composiciones relacionadas con el uso terapéutico de aminopiridinas en pacientes con un impedimento relacionado con un accidente cerebrovascular, en particular, en pacientes con un impedimento sensorial-motriz relacionado con el accidente cerebrovascular.
ARP120103710A 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas AR088764A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161543150P 2011-10-04 2011-10-04
US201261591833P 2012-01-27 2012-01-27
US201261648695P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
AR088764A1 true AR088764A1 (es) 2014-07-02

Family

ID=47143280

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103710A AR088764A1 (es) 2011-10-04 2012-10-04 Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas

Country Status (22)

Country Link
US (2) US20130085167A1 (es)
EP (1) EP2766017B1 (es)
JP (1) JP6134722B2 (es)
KR (1) KR20140084120A (es)
CN (2) CN104220072B (es)
AR (1) AR088764A1 (es)
AU (2) AU2012318719B2 (es)
BR (1) BR112014008082A8 (es)
CA (1) CA2850635A1 (es)
CL (1) CL2014000799A1 (es)
CO (1) CO7061067A2 (es)
CR (1) CR20140153A (es)
EA (1) EA029558B1 (es)
HK (1) HK1201204A1 (es)
IL (1) IL231809B (es)
MX (1) MX354667B (es)
PH (1) PH12014500739B1 (es)
SG (2) SG11201401248YA (es)
TW (1) TWI592156B (es)
UA (1) UA114486C2 (es)
WO (1) WO2013052575A1 (es)
ZA (1) ZA201402432B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1221666A1 (zh) * 2013-04-15 2017-06-09 Acorda Therapeutics, Inc. 氨基吡啶用於治療與某些中風類型相關的視覺障礙的方法
CN106511293B (zh) * 2015-09-11 2020-08-04 法德生技药品股份有限公司 含有达方吡啶的缓释口服制剂及其用途
DE102017115701B4 (de) 2017-07-12 2022-03-03 Lts Lohmann Therapie-Systeme Ag Fampridin-TTS
CN109172573B (zh) * 2018-09-12 2021-01-26 黑龙江中桂制药有限公司 一种口服抗血栓药物及其用途
CN115018836A (zh) * 2022-08-08 2022-09-06 四川大学 一种癫痫病灶自动分割与预测方法、系统及设备

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696575B2 (ja) * 1987-09-17 1994-11-30 三菱化成株式会社 ４−アミノピリジン誘導体及びその酸付加塩
JPH03505868A (ja) 1988-04-08 1991-12-19 マサチユセツツ・インスチチユート・オブ・テクノロジー 神経性疾患を治療するための方法及び組成物
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
CA2085785C (en) * 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
US5952357A (en) 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
DK1152760T3 (da) * 1999-02-09 2007-07-30 Uab Research Foundation Anvendelse af 4-aminopyridin til behandling af perifere neuropatier
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
WO2001072335A2 (en) * 2000-03-28 2001-10-04 Queen's University At Kingston Methods for effecting neuroprotection using a potassium channel modulator
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2008092167A2 (en) * 2007-01-26 2008-07-31 Safenet, Inc. Protecting secrets in an untrusted recipient
WO2012103471A1 (en) * 2011-01-28 2012-08-02 Acorda Therapeutics, Inc. Use of potassium channel blockers to treat cerebral palsy

Also Published As

Publication number Publication date
WO2013052575A1 (en) 2013-04-11
CN108451953A (zh) 2018-08-28
NZ623255A (en) 2016-08-26
MX354667B (es) 2018-03-15
JP2014531470A (ja) 2014-11-27
IL231809B (en) 2019-06-30
US20160067232A1 (en) 2016-03-10
EA029558B1 (ru) 2018-04-30
HK1204965A1 (en) 2015-12-11
CN104220072B (zh) 2018-04-17
ZA201402432B (en) 2020-08-26
PH12014500739A1 (en) 2014-05-26
CR20140153A (es) 2014-07-04
BR112014008082A2 (pt) 2017-07-18
CL2014000799A1 (es) 2014-11-03
EP2766017A1 (en) 2014-08-20
HK1201204A1 (en) 2015-08-28
UA114486C2 (uk) 2017-06-26
IL231809A0 (en) 2014-05-28
TW201321000A (zh) 2013-06-01
CN104220072A (zh) 2014-12-17
AU2012318719A1 (en) 2014-04-17
SG10201600410SA (en) 2016-02-26
SG11201401248YA (en) 2014-05-29
US20130085167A1 (en) 2013-04-04
BR112014008082A8 (pt) 2018-01-16
TWI592156B (zh) 2017-07-21
EP2766017B1 (en) 2020-07-01
CO7061067A2 (es) 2014-09-19
PH12014500739B1 (en) 2019-05-10
MX2014003997A (es) 2014-07-22
EA201490562A1 (ru) 2014-08-29
AU2012318719B2 (en) 2017-10-19
CA2850635A1 (en) 2013-04-11
KR20140084120A (ko) 2014-07-04
JP6134722B2 (ja) 2017-05-24
AU2018200114A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
AR089993A1 (es) Macrociclos peptidomimeticos
CU20120161A7 (es) 5-fluoro-1h-pirazolopiridinas sustituidas
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
MX2021000007A (es) Formulaciones de enzalutamida.
MX353827B (es) Formas de rifaximina y usos de la misma.
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
ECSP14026138A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2013002934A1 (es) Polimeros conjugados analogos de prostaglandinas; metodo de preparacion; implante y uso en el tratamiento del glaucoma.
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
BR112012028773A2 (pt) composições farmacêuticas compreendendo hidromorfona e naloxona
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
AR088764A1 (es) Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas
AR078323A1 (es) Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple
HRP20180345T1 (hr) Derivati sterola i njihova upotreba u liječenju bolesti koje uključuju transformirane astrocitne stanice, ili u liječenju zloćudnih hemopatija
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
EA201590782A1 (ru) Оксирановые амины
CU20130041A7 (es) Micobacteria recombinante como vacuna contra la tuberculosis para uso en humanos
DOP2015000290A (es) Benzoxazoles sustituidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure